Examining the Risks and Benefits of IPO Alternatives: Direct Listings & SPACS

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation involving this class of drugs.

The slow death of the Securities and Exchange Commission’s (SEC) climate disclosure rules continued on March 27, 2025, with the SEC Commissioners voting to discontinue the defense of such rules before the Eighth Circuit, Iowa v. SEC, No. 24-1522, which is where the numerous complaints challenging the rules were consolidated.

President Trump’s January 21 Executive Order targeting Diversity, Equity, and Inclusion Programs and, specifically, § 3(b)(iv)) cannot be the basis for liability — at least for one proactive litigant in the Northern District of Illinois. The holding could have broader implications for False Claims Act defendants concerned about evolving certification requirements.